Health
Affinity’s COVID-19 antibodies ready for manufacture for clinical trials – BSA bureau
The study offers a roadmap for speeding development of Monoclonal Antibodies for other diseases; Techniques applied to COVID-19 studies completed Phase 1 Trial
The study offers a roadmap for speeding development of Monoclonal Antibodies for other diseases; Techniques applied to COVID-19 studies completed Phase 1 Trial
Tychan, a Singapore-based clinical-stage biotechnology company focused on developing life-saving treatments through disruptive technologies, announced on 30 July 2020 a publication in New England Journal of Medicine (NEJM) demonstrating the safety and efficacy for TY014, a novel monoclonal antibody candidate treatment for yellow fever (Y…
-
Business24 hours agoIs Warren Buffett’s Berkshire Hathaway the smartest investment you can make today?
-
Noosa News10 hours agoCommissioner thanks police officer who threw a speed radar at a car
-
General24 hours agoTaiwan’s President Lai Ching-te calls for peace and dialogue with China while also calling for defence boosts
-
Noosa News18 hours agoCountdown on for Noosa Eat & Drink Festival 2025